On August 24, 2025, Harbour BioMed, a leading biopharmaceutical company headquartered in Cambridge, Mass., with offices in Rotterdam, Netherlands and Shanghai, shared that it is listed as HKEX: 02142. The company specializes in creating innovative antibody therapeutics for immunology and oncology. The announcement highlights their dedication to developing groundbreaking treatments in these fields.